HOME >> BIOLOGY >> NEWS
Nanotubes glow, even within biological cells

HOUSTON, Dec. 8, 2004 -- In some of the first work documenting the uptake of carbon nanotubes by living cells, a team of chemists and life scientists from Rice University, the University of Texas Health Science Center at Houston and the Texas Heart Institute have selectively detected low concentrations of nanotubes in laboratory cell cultures.

The research appears in the Dec. 8 issue of the Journal of the American Chemical Society. It suggests that the white blood cells, which were incubated in dilute solutions of nanotubes, treated the nanotubes as they would other extracellular particles actively ingesting them and sealing them off inside chambers known as phagosomes.

"Our goal in doing the experiment was both to learn how the biological function of the cells was affected by the nanotubes and to see if the fluorescent properties of the nanotubes would change inside a living cell," said lead researcher Bruce Weisman, professor of chemistry at Rice. "On the first point, we found no adverse effects on the cells, and on the second, we found that the nanotubes retained their unique optical properties, which allowed us to use a specialized microscope tuned to the near-infrared to pinpoint their locations within the cells."

The research builds upon Weisman's groundbreaking 2002 discovery that each of the dozens of varieties of semiconducting, single-walled carbon nanotubes (SWNTs) emits its own unique fluorescent signature.

The new findings suggest that SWNTs might be valuable biological imaging agents, in part because SWNTs fluoresce in the near-infrared portion of the spectrum, at wavelengths not normally emitted by biological tissues. This may allow light from even a handful of nanotubes to be selectively detected from within the body.

Carbon nanotubes are cylinders of carbon atoms that measure about one nanometer, or one-billionth of a meter, in diameter. They are larger than a molecule of water, but are about
'"/>

Contact: Jade Boyd
jadeboyd@rice.edu
713-348-6778
Rice University
9-Dec-2004


Page: 1 2

Related biology news :

1. Nanotubes used for first time to send signals to nerve cells
2. Nanotubes inspire new technique for healing broken bones
3. Gut check: Tracking the ecosystem within us
4. Study provides first genetic evidence of long-lived African presence within Britain
5. How are phenotypic differences between sexes related to phenotypic variation within sexes?
6. Antarctic research within the International Polar Year IPY 2007/08
7. Nerve fibers need specific growth factor chemical to form connections within the brain
8. Scientists discover a genetic code for organizing DNA within the nucleus
9. Drug dials down the energy within cells, UM researchers find
10. Rockefeller researchers discover a biological clock within a clock
11. Duke scientists explain gaps in nutrient availability within North Atlantic

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Nanotubes glow even within biological cells

(Date:4/10/2015)... Research and Markets ( http://www.researchandmarkets.com/research/cjk4gb/security ... Competitive Profiles - NEC" report to their offering. ... will continue to supply a range of IT security ... company focus on the development of a Big Data ... in the Asia-Pacific region is ...
(Date:4/8/2015)... , April 8, 2015  Infinisource, a ... and services, and Morpho, a leading supplier of ... to produce the market,s most advanced biometrically-enabled time ... iSolved NXG time clock is setting a bold, ... labor data for the small and mid-size employer. ...
(Date:4/2/2015)... 2, 2015 In the ... far outperforms the strongest competitors, showing outstanding performance ... the system is capable of a throughput of ... up to be ten times faster than most ... performance.      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ...
Breaking Biology News(10 mins):NEC Security Competitive Profile 2015 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
(Date:4/16/2015)... (PRWEB) April 16, 2015 Regis Technologies ... American Association for Cancer Research (AACR) annual meeting. Regis ... Convention Center, starting Saturday, April 18, in Philadelphia and ... claim to title of the oldest and largest organization ... fellowships and grants, and partners with survivors to promote ...
(Date:4/16/2015)... (PRWEB) April 16, 2015 ... at Charlotte (UNC Charlotte) spin-out company, announced today ... Cooper, Ph.D., M.D., as Chief Operating Officer (COO). ... of experience in developing clinical diagnostic and biotechnology ... infectious disease. , Cooper’s extensive career transcends the ...
(Date:4/16/2015)... 16, 2015  In recognition of World Hemophilia Day, ... groups to illuminate more than 15 prominent landmarks red throughout ... Boston,s Zakim Bridge and Prudential Tower, ... Mercedes-Benz Superdome and Denver,s ... of April 17, and coincide with hemophilia community events in ...
(Date:4/16/2015)... April 16, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: ... U.S. joint venture with G-treeBNT (ReGenTree LLC) has ... clinical trial for the orphan disorder, neurotrophic keratopathy ... dry eye syndrome (DES) in the U.S.  Both ... RGN-259/GBT201, this year.  Each of these eye disorders ...
Breaking Biology Technology:Regis Technologies Joins American Association for Cancer Research Annual Meeting 2OncoTAb Names Dr. David L. Cooper as COO 2Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 2Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 3Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5
Cached News: